In our current study, we demonstrate that NKG2A is a late inhibitory receptor expressed upon repeated cognate antigen stimulation, in contrast to inhibitory receptors PD‐1, TIGIT and LAG‐3, which are immediately expressed upon the first stimulation.

Jan 17, 2020 · Our findings demonstrate that tumor-infiltrating NKG2A + CD8 + T cells are the predominant subset of NKG2A + cells in human non-small cell lung carcinoma (NSCLC) and suggest that targeting NKG2A + CD8 + T cells is a promising approach for immunotherapy.

Mar 15, 2025 · We show that NKG2 a/c+ CD8 + T cells increase in the blood and intestine of AGM in response to SIVagm infection in contrast to SIVmac infection in macaques, the latter modeling HIV infection. NKG2 a/c+ CD8 + T cells were not expanded in lymph nodes, and CXCR5 + NKG2 a/c+ CD8 + T cell frequencies further decreased after SIV infection.

Dec 13, 2018 · NKG2A blockade therapy operated through CD8 T cells, but not NK cells. These findings indicate that NKG2A-blocking antibodies might improve clinical responses to therapeutic cancer vaccines.

Feb 15, 2022 · Naïve mouse CD8 T cells were synchronously and repeatedly activated by artificial antigen presenting cells in the presence of the homeostatic cytokine IL-7. The results revealed NKG2A as a late inhibitory receptor, expressed after repeated cognate antigen stimulations.

Jan 17, 2020 · Tumor-infiltrating NKG2A + CD8 + T cells expressed tissue-resident memory T cell (T RM cell) and exhausted T-cell markers. Cytokines and cytotoxic molecules secreted by tumor-infiltrating NKG2A + CD8 + T cells were significantly lower than …

There is mounting evidence of immune cell dysregulation in keloid scarring. In this study, we aimed to profile keloid scar tissues and blood cells and found that downregulation of cytotoxic CD8 + T cells is a keloid signature in the peripheral blood and keloid lesions.

Jan 23, 2024 · Clear cell renal cell carcinoma (ccRCC) harbors the highest expression of human leukocyte antigen E (HLA-E), ligand of NKG2A, among all solid tumors. In this study, we aim to investigate the role of NKG2A + CD8 + T cells in tumor microenvironment and its potential as a novel target in ccRCC.

Jan 17, 2022 · There is mounting evidence of immune cell dysregulation in keloid scarring. In this study, we aimed to profile keloid scar tissues and blood cells and found that downregulation of cytotoxic CD8 +...

Dec 15, 2015 · NKG2A functions intrinsically within ECTV-specific CD8 + T cells to limit excessive activation, prevent apoptosis, and preserve the specific CD8 + T cell response.